Brilacidin – QIDP Drug At a Critical Juncture
At around this time (July 2015), Cellceutix is expected to hammer out a Phase 3 program for brilacidin, its defensin-mimetic and host-defense protein (HDP) mimic structurally similar to magainin, with FDA. Brilacidin is certainly an interesting novel compound, coming from a new class, with a unique mode of action. It has Continue reading Brilacidin – QIDP Drug At a Critical Juncture